Literature DB >> 30393624

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Alfredo Addeo1, Giuseppe Luigi Banna2.   

Abstract

Entities:  

Year:  2018        PMID： 30393624      PMCID： PMC6193904          DOI： 10.21037/tlcr.2018.07.09

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  15 in total

1.  How to develop novel treatments for EGFR-mutant lung cancer.

Authors:  Giuseppe Luigi Banna; Marcello Tiseo
Journal:  Future Oncol       Date:  2015-08-13       Impact factor: 3.404

2.  EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.

Authors:  Zhong-Yi Dong; Jia-Tao Zhang; Si-Yang Liu; Jian Su; Chao Zhang; Zhi Xie; Qing Zhou; Hai-Yan Tu; Chong-Rui Xu; Li-Xu Yan; Yu-Fa Li; Wen-Zhao Zhong; Yi-Long Wu
Journal:  Oncoimmunology       Date:  2017-07-26       Impact factor: 8.110

3.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

4.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Authors:  Zhong-Yi Dong; Wen-Zhao Zhong; Xu-Chao Zhang; Jian Su; Zhi Xie; Si-Yang Liu; Hai-Yan Tu; Hua-Jun Chen; Yue-Li Sun; Qing Zhou; Jin-Ji Yang; Xue-Ning Yang; Jia-Xin Lin; Hong-Hong Yan; Hao-Ran Zhai; Li-Xu Yan; Ri-Qiang Liao; Si-Pei Wu; Yi-Long Wu
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

5.  Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

Authors:  Benjamin J Solomon; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Yiyun Tang; Keith D Wilner; Fiona Blackhall; Tony S Mok
Journal:  J Clin Oncol       Date:  2018-05-16       Impact factor: 44.544

Review 6.  Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.

Authors:  Alfredo Addeo; Fabrizio Tabbò; Tim Robinson; Lucio Buffoni; Silvia Novello
Journal:  Crit Rev Oncol Hematol       Date:  2017-12-30       Impact factor: 6.312

7.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

8.  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Wendy Cooper; Matthew Links; Val Gebski; Roy S Herbst; Richard J Gralla; Tony Mok; James Chih-Hsin Yang
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

9.  Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.

Authors:  K Haratani; H Hayashi; T Tanaka; H Kaneda; Y Togashi; K Sakai; K Hayashi; S Tomida; Y Chiba; K Yonesaka; Y Nonagase; T Takahama; J Tanizaki; K Tanaka; T Yoshida; K Tanimura; M Takeda; H Yoshioka; T Ishida; T Mitsudomi; K Nishio; K Nakagawa
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

Review 10.  Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy.

Authors:  Mirjana Efremova; Francesca Finotello; Dietmar Rieder; Zlatko Trajanoski
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561
View more
  3 in total

Review 1.  Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC.

Authors:  Alex Friedlaender; Giuseppe Banna; Sandip Patel; Alfredo Addeo
Journal:  Curr Treat Options Oncol       Date:  2019-09-04

Review 2.  New emerging targets in cancer immunotherapy: the role of TIM3.

Authors:  Alex Friedlaender; Alfredo Addeo; Giuseppe Banna
Journal:  ESMO Open       Date:  2019-06-12

3.  The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.

Authors:  Giuseppe Luigi Banna; Timothée Olivier; Francesco Rundo; Umberto Malapelle; Filippo Fraggetta; Massimo Libra; Alfredo Addeo
Journal:  Front Med (Lausanne)       Date:  2019-07-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.